PTLA Portola Pharmaceuticals Inc.

7.07
+0.62  (+10%)
Previous Close 6.45
Open 6.68
Price To Book 4.26
Market Cap 552,028,181
Shares 78,080,365
Volume 1,249,963
Short Ratio
Av. Daily Volume 1,600,758
Stock charts supplied by TradingView

NewsSee all news

  1. Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., April 1, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on March 31, 2020, the Compensation Committee of the Board of Directors approved, effective as

  2. Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)

    SOUTH SAN FRANCISCO, Calif., March 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced proactive steps the Company is taking in support of public heath efforts to prevent furtherspread

  3. Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds

    SOUTH SAN FRANCISCO, Calif., March 16, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced new data reinforcing the value of Andexxa® [coagulation factor Xa (recombinant),

  4. New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors

    SOUTH SAN FRANCISCO, Calif., March 5, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced the presentation of new data demonstrating that using Andexxa® [coagulation factor Xa (recombinant),

  5. Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., March 2, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on February 28, 2020, the Compensation Committee of the Board of Directors approved, effective

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval noted June 23, 2017.
Bevyxxa (betrixaban)
Venous thromboembolism (VTE) Prevention
Phase 2a data presented at ASH December 9, 2019. ORR 48%; 76% in combo cohort.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.
Andexxa
Factor Xa inhibitor reversal agent

Latest News

  1. Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., April 1, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on March 31, 2020, the Compensation Committee of the Board of Directors approved, effective as

  2. Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)

    SOUTH SAN FRANCISCO, Calif., March 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced proactive steps the Company is taking in support of public heath efforts to prevent furtherspread

  3. Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds

    SOUTH SAN FRANCISCO, Calif., March 16, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced new data reinforcing the value of Andexxa® [coagulation factor Xa (recombinant),

  4. New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors

    SOUTH SAN FRANCISCO, Calif., March 5, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced the presentation of new data demonstrating that using Andexxa® [coagulation factor Xa (recombinant),

  5. Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., March 2, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on February 28, 2020, the Compensation Committee of the Board of Directors approved, effective

  6. Portola Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today reported financial results for the fourth quarter and full year ended December 31, 2019.

  7. Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the Company will participate in the following conferences in March.

  8. Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for

  9. Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Feb. 3, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced the appointment of Rajiv Patni, M.D., as executive vice president and chief medical officer,

  10. Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million

    SOUTH SAN FRANCISCO, Calif., Jan. 9, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced preliminary unaudited Andexxa global net revenues for the fourth quarter and full year 2019. For the

  11. Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020

    SOUTH SAN FRANCISCO, Calif., Dec. 23, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2020.

  12. Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke

    SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced its support of the American Heart Association®/American Stroke Association's® newest initiative

  13. Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

    SOUTH SAN FRANCISCO, Calif., Dec. 9, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an

  14. Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

    SOUTH SAN FRANCISCO, Calif., Dec. 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an

  15. Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians

  16. Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an

  17. Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update.

  18. Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Nov. 1, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as

  19. Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019

    SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for

  20. Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry

  21. Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 22, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual